Nov. 14, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its oral insulin capsule ORMD-0801 in patients with nonalcoholic steatohepatitis (NASH). The proposed three-month treatment study will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Oramed plans on initiating the study in the coming month.
- World first MRI for the NeoNatal ICU has been successfully working at Jerusalem’s Shaare Zedek Medical Center for the last three months
- BioCanCell Announces Updated Results from the Phase II Clinical Trial of BC-819 and BCG in Patients With Bladder Cancer